SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology…


Previous articleSecond United States Patent Granted for Small Pharma’s Psychedelics Portfolio
Next articleatai Life Sciences Announces R&D Day Agenda